141 related articles for article (PubMed ID: 35189080)
1. Decoupling of omicron variant infections and severe COVID-19.
Madhi SA; Ihekweazu C; Rees H; Pollard AJ
Lancet; 2022 Mar; 399(10329):1047-1048. PubMed ID: 35189080
[No Abstract] [Full Text] [Related]
2. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
Nemet I; Kliker L; Lustig Y; Zuckerman N; Erster O; Cohen C; Kreiss Y; Alroy-Preis S; Regev-Yochay G; Mendelson E; Mandelboim M
N Engl J Med; 2022 Feb; 386(5):492-494. PubMed ID: 34965337
[No Abstract] [Full Text] [Related]
3. Audio Interview: The Omicron Variant of SARS-CoV-2.
Rubin EJ; Baden LR; Abdool Karim SS; Morrissey S
N Engl J Med; 2021 Dec; 385(23):e96. PubMed ID: 34874638
[No Abstract] [Full Text] [Related]
4. Metabolic disorders, COVID-19 and vaccine-breakthrough infections.
Stefan N
Nat Rev Endocrinol; 2022 Feb; 18(2):75-76. PubMed ID: 34873287
[TBL] [Abstract][Full Text] [Related]
5. A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.
Minka SO; Minka FH
Immunol Lett; 2022 Mar; 243():38-43. PubMed ID: 35131373
[TBL] [Abstract][Full Text] [Related]
6. Plasma Neutralization of the SARS-CoV-2 Omicron Variant.
Schmidt F; Muecksch F; Weisblum Y; Da Silva J; Bednarski E; Cho A; Wang Z; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
N Engl J Med; 2022 Feb; 386(6):599-601. PubMed ID: 35030645
[No Abstract] [Full Text] [Related]
7. Scientists see a 'really, really tough winter' with Omicron.
Kupferschmidt K
Science; 2021 Dec; 374(6574):1421-1422. PubMed ID: 34914506
[No Abstract] [Full Text] [Related]
8. Vaccine-breakthrough infection by the SARS-CoV-2 omicron variant elicits broadly cross-reactive immune responses.
Zhou R; To KK; Peng Q; Chan JM; Huang H; Yang D; Lam BH; Chuang VW; Cai JP; Liu N; Au KK; Tsang OT; Yuen KY; Chen Z
Clin Transl Med; 2022 Jan; 12(1):e720. PubMed ID: 35083867
[No Abstract] [Full Text] [Related]
9. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 vaccine breakthrough infections.
Gupta RK; Topol EJ
Science; 2021 Dec; 374(6575):1561-1562. PubMed ID: 34941414
[TBL] [Abstract][Full Text] [Related]
11. Audio Interview: Covid-19 Vaccination and the Omicron Variant.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Dec; 385(27):e102. PubMed ID: 34965346
[No Abstract] [Full Text] [Related]
12. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
Wang Y
EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
[No Abstract] [Full Text] [Related]
13. Omicron likely to weaken COVID vaccine protection.
Callaway E
Nature; 2021 Dec; 600(7889):367-368. PubMed ID: 34880488
[No Abstract] [Full Text] [Related]
14. Vaccine booster efficiently inhibits entry of SARS-CoV-2 omicron variant.
Zhang W; Huang L; Ye G; Geng Q; Ikeogu N; Harris M; Dileepan G; Burrack K; Du L; Frosch A; Li F
Cell Mol Immunol; 2022 Mar; 19(3):445-446. PubMed ID: 35075267
[No Abstract] [Full Text] [Related]
15. Omicron sparks a vaccine strategy debate.
Cohen J
Science; 2021 Dec; 374(6575):1544-1545. PubMed ID: 34941399
[No Abstract] [Full Text] [Related]
16. A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines.
Zhang N; Li K; Liu Z; Nandakumar KS; Jiang S
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215980
[TBL] [Abstract][Full Text] [Related]
17. Variant-adapted COVID-19 booster vaccines.
Krammer F; Ellebedy AH
Science; 2023 Oct; 382(6667):157-159. PubMed ID: 37824671
[TBL] [Abstract][Full Text] [Related]
18. Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera.
Zhou W; He P; Li J; Liu H; Shi M; Yu J; Wei H
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215927
[TBL] [Abstract][Full Text] [Related]
19. Omicron: Call for updated vaccines.
Li X
J Med Virol; 2022 Apr; 94(4):1261-1263. PubMed ID: 34927258
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.
Danza P; Koo TH; Haddix M; Fisher R; Traub E; OYong K; Balter S
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(5):177-181. PubMed ID: 35113851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
